Insulin-like growth factor binding protein-3 is overexpressed in endothelial cells of mouse breast tumor vessels

International Journal of Cancer

Volumn 103, Issue 5, 2003, Pages 577-586

  Schmid, Michael C ^a   Bisoffi, Marco ^a   Wetterwald, Antoinette ^a   Gautschi, Elsbeth ^a   Thalmann, George N ^a   Mitola, Stefania ^b   Bussolino, Federico ^b   Cecchini, Marco G ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b CANDIOLO CANCER INSTITUTE   (Italy)

Author keywords

Angiogenesis; Antiangiogenesis; Gene profile; IGFBP 3; Tumor endothelium

Indexed keywords

ANGIOGENESIS INHIBITOR; SOMATOMEDIN BINDING PROTEIN 3;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST TUMOR; CANCER DIAGNOSIS; CELL ISOLATION; CELL POPULATION; CONTROLLED STUDY; DISEASE MARKER; DNA MICROARRAY; DNA PROBE; DRUG TARGETING; ENDOTHELIUM CELL; GENE OVEREXPRESSION; IMMUNOMAGNETIC SEPARATION; ISOGRAFT; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA HYBRIDIZATION; TUMOR VASCULARIZATION;

ANIMALS; ANTIGENS, CD31; DNA PRIMERS; ENDOTHELIUM, VASCULAR; FEMALE; GENE EXPRESSION PROFILING; IMMUNOENZYME TECHNIQUES; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; LIPOPROTEINS, LDL; LIVER; MACROPHAGES; MAMMARY GLANDS, ANIMAL; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; NEOVASCULARIZATION, PATHOLOGIC; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 0037455811     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10874     Document Type: Article

References (71)

1. Liekens A, De Clercq E, Neyts J. Angiogenesis: regulators and clinical applications. Biochem Pharmacol 2001;61:253-70.
2. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86;353-64.
3. Klagsbrun M, Moses MA. Molecular angiogenesis. Chem Biol 1999; 6:R217-24.
4. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature 2000;407:242-8.
5. Conway EM, Collen D, Carmeliet P. Molecular mechanisms of blood vessel growth. Cardiovasc Res 2001;49:507-21.
6. Folkman J. Tumor angiogenesis. In: Holland J, Bast RJ, Morton D, Frei E III, Kufe D, Weichselbaum R, eds. Cancer medicine. Baltimore: Williams & Wilkins, 1997. 181-204.
7. Fidler IJ. Angiogenesis and cancer metastasis. Cancer J Sci Am 2000;6;S134-41.
8. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249-57.
9. Zetter BR. Angiogenesis and tumor metastasis. Annu Rev Med 1998; 49:407-24.
10. Weidner N. Tumoural vascularity as a prognostic factor in cancer patients: the evidence continues to grow. J Pathol 1998;184:119-22.
11. Fox SB, Gasparini G, Harris AL. Angiogenesis: pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs. Lancet 2001;2:278-89.
12. Hasan J, Byers R, Jayson GC. Intra-tumoural microvessel density in human solid tumours. Br J Cancer 2002;86:1566-77.
13. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994;79:315-28.
14. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88:277-85.
15. Thorpe PE, Burrows FJ. Antibody-directed targeting of the vasculature of solid tumors. Breast Cancer Res Treat 1995;36:237-51.
16. Page C, Rose M, Yacoub M, Pigott R. Antigenic heterogeneity of vascular endothelium. Am J Pathol 1992;141:673-83.
17. Garlanda C, Dejana E. Heterogeneity of endothelial cells. Specific markers. Arterioscler Thromb Vasc Biol 1997;17:1193-202.
18. Carey DJ. Control of growth and differentiation of vascular cells by extracellular matrix proteins. Annu Rev Physiol 1991;53:161-77.
19. Madri JA. Extracellular matrix modulation of vascular cell behaviour. Transpl Immunol 1997;5:179-83.
20. Schlosshauer B. The blood-brain barrier: morphology, molecules, and neurothelin. Bioessays 1993;15:341-6.
21. Molema G, de Leij LF, Meijer DK. Tumor vascular endothelium: barrier or target in tumor directed drug delivery and immunotherapy. Pharm Res 1997;14:2-10.
22. Griffioen AW. Phenotype of the tumor vasculature: cell adhesion as a target for tumor therapy. Cancer J 1997;10:249-55.
23. St. Croix B, Rago C, Velculescu V, Traverso G, Romans KE, Montgomery E, Lal A, Riggins GJ, Lengauer C, Vogelstein B, Kinzler KW. Genes expressed in human tumor endothelium. Science 2000;289: 1197-202.
24. Carson-Walter EB, Watkins DN, Nanda A, Vogelstein B, Kinzler KW, St Croix B. Cell surface tumor endothelial markers are conserved in mice and humans. Cancer Res 2001;61:6649-55.
25. Lockhart DJ, Winzeler EA. Genomics, gene expression and DNA arrays. Nature 2000;405:827-36.
26. Morrison BW, Leder P. neu and ras initiate murine mammary tumors that share genetic markers generally absent in c-myc and int-2-initiated tumors. Oncogene 1994;9:3417-26.
27. Lelekakis M, Moseley JM, Martin TJ, Hards D, Williams E, Ho P, Lowen D, Javni J, Miller FR, Slavin J, Anderson RL. A novel orthotopic model of breast cancer metastasis to bone. Clin Exp Metastasis 1999;17:163-70.
28. Muller WJ, Sinn E, Pattengale PK, Wallace R, Leder P. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 1988;54:105-15.
29. Buma P, Groenenberg M, Rijken PF, van den Berg WB, Joosten L, Peters H. Quantitation of the changes in vascularity during arthritis in the knee joint of a mouse with a digital image analysis system. Anat Rec 2001;262:420-8.
30. Dong QG, Bernasconi S, Lostaglio S, De Calmanovici RW, Martin-Padura I, Breviario F, Garlanda C, Ramponi S, Mantovani A, Vecchi A. A general strategy for isolation of endothelial cells from murine tissues. Characterization of two endothelial cell lines from the murine lung and subcutaneous sponge implants. Arterioscler Thromb Vasc Biol 1997;17:1599-604.
31. Vecchi A, Garlanda C, Lampugnani MG, Resnati M, Matteucci C, Stoppacciaro A, Schnurch H, Risau W, Ruco L, Mantovani A. Monoclonal antibodies specific for endothelial cells of mouse blood vessels. Their application in the identification of adult and embryonic endothelium. Eur J Cell Biol 1994;63:247-54.
32. Voyta JC, Via DP, Butterfield CE, Zetter BR. Identification and isolation of endothelial cells based on their increased uptake of acetylated-low density lipoprotein. J Cell Biol 1984;99:2034-40.
33. McKenney JK, Weiss SW, Folpe AL. CD31 expression in intratumoral macrophages: a potential diagnostic pitfall. Am J Surg Pathol 2001;25:1167-73.
34. Xie Y, Chen C, Hume DA. Transcriptional regulation of c-fms gene expression. Cell Biochem Biophys 2001;34:1-16.
35. Glienke J, Schmitt AO, Pilarsky C, Hinzmann B, Weiss B, Rosenthal A, Thierauch KH. Differential gene expression by endothelial cells in distinct angiogenic states. Eur J Biochem 2000;267:2820-30.
36. Kahn J, Mehraban F, Ingle G, Xin X, Bryant JE, Vehar G, Schoenfeld J, Grimaldi CJ, Peale F, Draksharapu A, Lewin DA, Gerritsen ME. Gene expression profiling in an in vitro model of angiogenesis. Am J Pathol 2000;156:1887-900.
37. Vanzulli S, Gazzaniga S, Braidot MF, Vecchi A, Mantovani A, Wainstok de Calmanovici R. Detection of endothelial cells by MEC 13.3 monoclonal antibody in mice mammary tumors. Biocell 1997; 21:39-46.
38. van Kleffens M, Groffen CA, Dits NF, Lindenbergh-Kortleve DJ, Schuller AG, Bradshaw SL, Pintar JE, Zwarthoff EC, Drop SL, van Neck JW. Generation of antisera to mouse insulin-like growth factor binding proteins (IGFBP)-1 to -6: comparison of IGFBP protein and messenger ribonucleic acid localization in the mouse embryo. Endocrinology 1999;140:5944-52.
39. Ferry RJ Jr, Cerri RW, Cohen P. Insulin-like growth factor binding proteins: new proteins, new functions. Horm Res 1999;51:53-67.
40. Schuller AG, Groffen C, van Neck JW, Zwarthoff EC, Drop SL. cDNA cloning and mRNA expression of the six mouse insulin-like growth factor binding proteins. Mol Cell Endocrinol 1994;104:57-66.
41. Hwa V, Oh Y, Rosenfeld RG. The insulin-like growth factor-binding protein (IGFBP) superfamily. Endocr Rev 1999;20:761-87.
42. Kelley KM, Oh Y, Gargosky SE, Gucev Z, Matsumoto T, Hwa V, Ng L, Simpson DM, Rosenfeld RG. Insulin-like growth factor-binding proteins (IGFBPs) and their regulatory dynamics. Int J Biochem Cell Biol 1996;28:619-37.
43. Zimmermann EM, Li L, Hoyt EC, Pucilowska JB, Lichtman S, Lund PK. Cell-specific localization of insulin-like growth factor binding protein mRNAs in rat liver. Am J Physiol 2000;278:G447-57.
44. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE, Pollak M. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998;351:1393-6.
45. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollak M. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998;279:563-6.
46. Ma J, Pollak MN, Giovannucci E, Chan JM, Tao Y, Hennekens CH, Stampfer MJ. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 1999;91:620-5.
47. Yu H, Spitz MR, Mistry J, Gu J, Hong WK, Wu X. Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J Natl Cancer Inst 1999;91:151-6.
48. Cohen P, Clemmons DR, Rosenfeld RG. Does the GH-IGF axis play a role in cancer pathogenesis? Growth Horm IGF Res 2000;10:297-305.
49. Grimberg A, Cohen P. Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis. J Cell Physiol 2000;183:1-9.
50. Stattin P, Bylund A, Rinaldi S, Biessy C, Dechaud H, Stenman UH, Egevad L, Riboli E, Hallmans G, Kaaks R. Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study. J Natl Cancer Inst 2000;92:1910-7.
51. Renehan AG, Painter JE, Atkin WS, Potten CS, Shalet SM, O'Dwyer ST. High-risk colorectal adenomas and serum insulin-like growth factors. Br J Surg 2001;88:107-13.
52. Furstenberger G, Senn HJ. Insulin-like growth factors and cancer. Lancet Oncol 2002;3:298-302.
53. De Mellow JS, Baxter RC. Growth hormone-dependent insulin-like growth factor (IGF) binding protein both inhibits and potentiates IGF-I-stimulated DNA synthesis in human skin fibroblasts. Biochem Biophys Res Commun 1988;156:199-204.
54. Oh Y, Muller HL, Pham H, Rosenfeld RG. Demonstration of receptors for insulin-like growth factor binding protein-3 on Hs578T human breast cancer cells. J Biol Chem 1993;268:26045-8.
55. Yamanaka Y, Fowlkes JL, Wilson EM, Rosenfeld RG, Oh Y. Characterization of insulin-like growth factor binding protein-3 (IGFBP-3) binding to human breast cancer cells: kinetics of IGFBP-3 binding and identification of receptor binding domain on the IGFBP-3 molecule. Endocrinology 1999;140:1319-28.
56. Gill ZP, Perks CM, Newcomb PV, Holly JM. Insulin-like growth factor-binding protein (IGFBP-3) predisposes breast cancer cells to programmed cell death in a non-IGF-dependent manner. J Biol Chem 1997;272:25602-7.
57. Rajah R, Valentinis B, Cohen P. Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-beta1 on programmed cell death through a p53-and IGF-independent mechanism. J Biol Chem 1997;272:12181-8.
58. Nickerson T, Huynh H, Pollak M. Insulin-like growth factor binding protein-3 induces apoptosis in MCF7 breast cancer cells. Biochem Biophys Res Commun 1997;237:690-3.
59. Baxter RC. Signaling pathways involved in antiproliferative effects of IGFBP-3: a review. Mol Pathol 2001;54:145-8.
60. Fanayan S, Firth SM, Baxter RC. Signaling through the Smad pathway by insulin-like growth factor-binding protein-3 in breast cancer cells. Relationship to transforming growth factor-beta 1 signaling. J Biol Chem 2002;277:7255-61.
61. Erickson GF, Nakatani A, Ling N, Shimasaki S. Insulin-like growth factor binding protein-3 gene expression is restricted to involuting corpora lutea in rat ovaries. Endocrinology 1993;133:1147-57.
62. Fraser HM, Lunn SF, Kim H, Erickson GF. Insulin-like growth factor binding protein-3 mRNA expression in endothelial cells of the primate corpus luteum. Hum Reprod 1998;13:2180-5.
63. Fraser HM, Lunn SF, Kim H, Duncan WC, Rodger FE, Illingworth PJ, Erickson GF. Changes in insulin-like growth factor-binding protein-3 messenger ribonucleic acid in endothelial cells of the human corpus luteum: a possible role in luteal development and rescue. J Clin Endocrinol Metab 2000;85:1672-7.
64. Kluge A, Zimmermann R, Weihrauch D, Mohri M, Sack S, Schaper J, Schaper W. Coordinate expression of the insulin-like growth factor system after microembolisation in porcine heart. Cardiovasc Res 1997;33:324-31.
65. Tucci M, Nygard K, Tanswell BV, Farber HW, Hill DJ, Han VK. Modulation of insulin-like growth factor (IGF) and IGF binding protein biosynthesis by hypoxia in cultured vascular endothelial cells. J Endocrinol 1998;157:13-24.
66. Lee WH, Wang GM, Yang XL, Seaman LB, Vannucci SI. Perinatal hypoxia-ischemia decreased neuronal but increased cerebral vascular endothelial IGFBP3 expression. Endocrine 1999;11:181-8.
67. Akaogi K, Okabe Y, Sato J, Nagashima Y, Yasumitsu H, Sugahara K, Miyazaki K. Specific accumulation of tumor-derived adhesion factor in tumor blood vessels and in capillary tube-like structures of cultured vascular endothelial cells. Proc Natl Acad Sci USA 1996;93:8384-9.
68. Korc-Grodzicki B, Ren N, Hilf R. Insulin-like growth factor-binding proteins in R3230AC mammary tumors of intact and diabetic rats. Endocrinology 1993;133:2362-70
69. Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, Zagzag D, Yancopoulos GD, Wiegand SJ. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999;284:1994-8.
70. Findlay JK, Drummond AE, Dyson ML, Baillie AJ, Robertson DM, Ethier JF. Recruitment and development of the follicle; the roles of the transforming growth factor-beta superfamily. Mol Cell Endocrinol 2002;191:35-43.
71. Zorn AM. Wnt signaling: antagonistic Dickkopfs. Curr Biol 2001;11: R592-5.